Baseline characteristics of unmatched and matched cohorts using abatacept or an anti-TNF with follow-up at 6 months
| Unmatched | Matched | |||||
|---|---|---|---|---|---|---|
| ABA (N=440) | Anti-TNF (N=958) | p Value | ABA (N=431) | Anti-TNF (N=746) | p Value | |
| Demographics | ||||||
| Age (mean age, SD) | 57.7 (12.4) | 55.6 (12.5) | 0.003 | 57.6 (12.4) | 57.2 (11.7) | 0.578 |
| Gender (% female) | 82.7 | 80.0 | 0.242 | 82.4 | 79.1 | 0.196 |
| Race (% white) | 81.8 | 85.4 | 0.097 | 82.4 | 85.1 | 0.216 |
| Insurance (%) | ||||||
| Private | 78.6 | 79.3 | 0.830 | 79.4 | 81.0 | 0.542 |
| Medicare | 36.8 | 29.8 | 0.012 | 36.4 | 30.8 | 0.053 |
| Medicaid | 5.0 | 6.9 | 0.188 | 5.1 | 6.4 | 0.374 |
| Clinical | ||||||
| Rheumatoid factor seropositivity (%) | 71.3 | 78.0 | 0.032 | 70.7 | 80.0 | 0.006 |
| Disease duration (mean years, SD) | 13.4 (10.3) | 11.5 (9.4) | 0.000 | 13.3 (10.0) | 12.1 (9.8) | 0.045 |
| Tender joints, N (SD) | 7.4 (7.1) | 7.3 (7.1) | 0.717 | 7.4 (7.1) | 7.3 (7.1) | 0.811 |
| Swollen joints, N (SD) | 6.8 (6.0) | 5.9 (5.3) | 0.005 | 6.7 (5.9) | 6.1 (5.2) | 0.087 |
| Patient pain score (mean, SD) | 52.7 (25.3) | 49.3 (25.8) | 0.023 | 52.7 (25.5) | 50.2 (25.8) | 0.112 |
| mHAQ (mean, SD) | 0.7 (0.5) | 0.6 (0.5) | 0.012 | 0.7 (0.5) | 0.6 (0.5) | 0.047 |
| CDAI (mean, SD) | 22.9 (14.1) | 21.4 (13.2) | 0.057 | 22.8 (14.1) | 21.7 (12.9) | 0.182 |
| Disease activity* (%) | 0.210 | 0.354 | ||||
| Low | 19.8 | 20.6 | 20.2 | 19.0 | ||
| Moderate | 35.7 | 39.8 | 35.7 | 40.0 | ||
| High | 44.6 | 39.7 | 44.1 | 41.0 | ||
| Concomitant medications | ||||||
| Corticosteroids, (%) | 40.0 | 34.0 | 0.036 | 39.4 | 33.0 | 0.027 |
| Leflunomide, (%) | 12.5 | 12.7 | 0.931 | 12.5 | 13.3 | 0.787 |
| MTX, (%) | 54.8 | 57.1 | 0.417 | 55.2 | 55.5 | 0.951 |
| Dose, mg/week (SD) | 16.3 (6.2) | 16.4 (6.0) | 0.843 | 16.3 (6.2) | 16.2 (5.9) | 0.906 |
ABA, abatacept; anti-TNF, anti-tumour necrosis factor; CDAI, Clinical Disease Activity Index; mHAQ, modified Health Assessment Questionnaire; MTX, methotrexate.
*Disease activity based on the CDAI.